Improving the assessment of prescribing: use of a 'substitution index'.

To analyse the current and potential utilization of generic drugs in Japan, to examine the maximum possible cost savings from generic drug use and to develop a fairer measure to assess the level of generic drug substitution.
We conducted a cross-sectional retrospective analysis of nine million dispensing records during January to March 2010 in Kyoto Prefecture. Maximum potential quantity-based shares were defined as the quantity of generic drugs used plus the quantity of branded drugs that could have been replaced by generic drugs divided by the quantity of all drugs dispensed. We developed a 'substitution index', defined as the proportion of generic drugs out of the total drugs substitutable with generic drugs (based on quantity rather than cost).
Generic drugs had a quantity-based share of 17.9%, a cost-based share of 8.9% and a maximum potential quantity-based share of 50.1%, which is lower than the actual generic drug shares of some other countries. The maximum possible cost savings as a result of generic drug substitution was 16.5%. We also observed wide variations in maximum potential quantity-based shares between health care sectors and health care institutions.
Simple comparisons based on quantity-based shares may misrepresent the actual generic drug use. A substitution index that takes into account the maximum potential quantity-based share of generic drugs as a fairer measure may promote more realistic goals and encourage generic drug usage.
AuthorsSusumu Kunisawa, Tetsuya Otsubo, Jason Lee, Yuichi Imanaka
JournalJournal of health services research & policy (J Health Serv Res Policy) Vol. 18 Issue 3 Pg. 138-43 (Jul 2013) ISSN: 1758-1060 [Electronic] England
PMID23595576 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Drugs, Generic
  • Prescription Drugs
  • Cost Savings
  • Cross-Sectional Studies
  • Databases, Factual
  • Drug Substitution (economics)
  • Drugs, Generic (economics, therapeutic use)
  • Humans
  • Japan
  • Prescription Drugs (economics, therapeutic use)
  • Retrospective Studies
  • Therapeutic Equivalency

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: